Fig. 6
From: Serotonin signals through a gut-liver axis to regulate hepatic steatosis
HTR2A antagonist ameliorates HFD-induced hepatic steatosis. a–g The 12-week-old mice were fed SCD or HFD for 8 weeks and were treated with vehicle or sarpogrelate daily per os. a Representative liver histology by H&E staining from HFD-fed vehicle and sarpogrelate treated mice. Scale bars, 100 μm. b NAS of HFD-fed vehicle and sarpogrelate-treated mice; n = 6 per group. c Hepatic triglyceride levels; n = 5–6 per group. d–g Relative mRNA expression of genes involved in lipogenesis (d), FA uptake (e), FA oxidation (f), and VLDL secretion (g) as assessed by qRT-PCR in liver; n = 5 per group. Data are expressed as the means ± SEM. *P < 0.5, **P < 0.01, ***P < 0.001, Student’s t-test (b) or one-way ANOVA with post hoc Tukey’s test (c–g)
